It looks like you're offline.
Open Library logo
additional options menu

MARC Record from Library of Congress

Record ID marc_loc_updates/v37.i52.records.utf8:28159231:2346
Source Library of Congress
Download Link /show-records/marc_loc_updates/v37.i52.records.utf8:28159231:2346?format=raw

LEADER: 02346nam a22002777a 4500
001 2009655825
003 DLC
005 20091228105841.0
007 cr |||||||||||
008 091228s2009 mau sb 000 0 eng
010 $a 2009655825
040 $aDLC$cDLC
050 00 $aHB1
245 03 $aAn economic evaluation of the war on cancer$h[electronic resource] /$cEric C. Sun, Anupam B. Jena, Darius N. Lakdawalla, Carolina M. Reyes, Tomas J. Philipson, Dana P. Goldman.
260 $aCambridge, MA :$bNational Bureau of Economic Research,$cc2009.
490 1 $aNBER working paper series ;$vworking paper 15574
538 $aSystem requirements: Adobe Acrobat Reader.
538 $aMode of access: World Wide Web.
500 $aTitle from PDF file as viewed on 12/28/2009.
530 $aAlso available in print.
504 $aIncludes bibliographical references.
520 3 $a"The NBER Bulletin on Aging and Health provides summaries of publications like this. You can sign up to receive the NBER Bulletin on Aging and Health by email. For decades, the US public and private sectors have committed substantial resources towards cancer research, but the societal payoff has not been well-understood. We quantify the value of recent gains in cancer survival, and analyze the distribution of value among various stakeholders. Between 1988 and 2000, life expectancy for cancer patients increased by roughly four years, and the average willingness-to-pay for these survival gains was roughly $322,000. Improvements in cancer survival during this period created 23 million additional life-years and roughly $1.9 trillion of additional social value, implying that the average life-year was worth approximately $82,000 to its recipient. Health care providers and pharmaceutical companies appropriated 5-19% of this total, with the rest accruing to patients. The share of value flowing to patients has been rising over time. These calculations suggest that from the patient's point of view, the rate of return to R&D investments against cancer has been substantial"--National Bureau of Economic Research web site.
700 1 $aSun, Eric.
710 2 $aNational Bureau of Economic Research.
830 0 $aWorking paper series (National Bureau of Economic Research : Online) ;$vworking paper no. 15574.
856 40 $uhttp://www.nber.org/papers/w15574